Long-term prolactin excess is often accompanied by numerous metabolic complications. No previous study has compared the effect of statin therapy on circulating levels of cardiometabolic risk factors in patients with elevated and normal prolactin levels. The study population consisted of 3 age-, weight-, and lipid-matched groups of young women: 19 women with untreated hyperprolactinemia (group A), 20 normoprolactinemic women receiving bromocriptine treatment (because of previous hyperprolactinemia) (group B), and 20 untreated women with prolactin levels within the reference range (group C). Because of elevated total and low-density lipoprotein cholesterol levels, all women were then treated with atorvastatin (40 mg daily). Apart from measuring plasma lipids, glucose homeostasis markers, and hormone levels at the beginning of the study and 12 weeks later, we measured circulating levels of uric acid, high-sensitivity C-reactive protein, homocysteine, and fibrinogen. Despite similar baseline levels of plasma lipids, levels of uric acid, high-sensitivity C-reactive protein, homocysteine, and fibrinogen as well as the degree of insulin resistance were higher in group A than in the remaining 2 groups. Atorvastatin reduced total and low-density lipoprotein cholesterol levels in all study groups. However, only in normoprolactinemic women (groups B and C) did atorvastatin reduce circulating levels of nonlipid cardiometabolic risk factors, whereas only in group A did the drug slightly impair insulin sensitivity. The results of the study suggest that cardiometabolic effects of atorvastatin depend on the prolactin status of patients.
Large clinical trials have shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce cardiovascular morbidity and mortality. [1] [2] [3] For this reason statins are the drugs of choice in the treatment of dyslipidemia and cardiovascular disease. 4 Moreover, statins were found to be beneficial for treating numerous other disorders, including diabetes mellitus, multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, systemic lupus erythematosus, Parkinson and Alzheimer diseases, cancer, and chronic obstructive pulmonary disease. 5, 6 Clinical benefits cannot be explained exclusively by the lipid-lowering properties of HMG-CoA reductase inhibitors but also by extralipid, so-called "pleiotropic" effects. Non-lipid-related mechanisms of statin action include anti-inflammatory and antioxidative actions, immunomodulatory effects, cytoprotection of vascular endothelium, regulation of smooth muscle cell proliferation and migration, and favorable effects on coagulation, fibrinolysis, and platelet activities. 7, 8 It seems that prolactin excess may be involved in the development and progression of atherosclerosis. Essential hypertension was characterized by increased prolactin levels, and bromocriptine treatment, in addition to reducing prolactin levels, lowered blood pressure. 9 Prolactin levels positively correlated with central aortic systolic and diastolic blood pressures and with pulse wave velocity 10 but inversely correlated with flow-mediated dilatation of the brachial artery and insulin sensitivity. 11 Moreover, prolactin excess was characterized by increased homocysteine levels 11 as well as by enhanced thrombin generation and elevated D-dimer levels. 12 Withdrawal of cabergoline therapy resulted in negative changes in flow-mediated dilatation of the brachial artery and carotid intimamedia thickness and was accompanied by an increase in plasma fibrinogen. 13 Elevated prolactin levels were found in patients with acute coronary symptoms, with the highest values observed in subjects with myocardial infarction.
14 Moreover, hyperprolactinemia seems to be a risk factor for ischemic stroke 15 and venous thromboembolism, 16 and this association is, at least in part, attributed to a stimulatory effect of this hormone on platelet activation. Finally, in the population-based Study of Health in Pomerania, prolactin concentrations were correlated with all-cause mortality and cardiovascular mortality. 17 In the Framingham Heart Study, however, after patients with elevated prolactin levels had been excluded, measurement of prolactin did not provide substantial insight into cardiometabolic risk. 18 In the light of our recent studies, it seems that pleiotropic effects of hypolipidemic agents may be attenuated by some endocrine and metabolic disturbances. A negative effect on extralipid effects of statins was exerted by untreated subclinical hypothyroidism and by low vitamin D status. 19, 20 Moreover, subclinical hypothyroidism had a negative effect on non-lipidrelated effects of fenofibrate. 21 Because of the lack of similar studies in the current literature, we decided to investigate whether the prolactin status of a patient determines the strength of atorvastatin action on plasma levels of lipids and extralipid cardiometabolic risk factors.
Methods
The study protocol was approved by our institutional review board (the Bioethical Committee of the Medical University of Silesia), and all participants signed informed consent after careful explanation of the study procedures.
Patients
The participants of the study were recruited among adult women (aged 18-50 years) with isolated hypercholesterolemia (total cholesterol levels more than 200 mg/dL, low-density lipoprotein [LDL] cholesterol levels above 130 mg/dL, and triglycerides less than 150 mg/dL), complying with lifestyle intervention for at least 3 months before the beginning of the study. They were required to have a personal history of hyperprolactinemia and/or at least 1 of the symptoms or signs suggestive of elevated prolactin levels (oligomenorrhea, galactorrhea, infertility, or empty sella syndrome). On the basis of plasma prolactin levels, assessed on 2 different occasions, and dopamine agonist treatment, the patients were enrolled into 1 of 3 groups: (A) women with untreated hyperprolactinemia (plasma prolactin levels in the range between 30 and 60 ng/mL, n = 19); (B) normoprolactinemic women treated, because of hyperprolactinemia, for at least 12 weeks with bromocriptine (5.0-7.5 mg daily, n = 20 [Subjects treated with bromocriptine for a shorter period of time were offered atorvastatin treatment but were not participants of the study.]); and (C) untreated normoprolactinemic women (n = 20). Normoprolactinemia was defined as plasma prolactin levels at least 5 mg/dL but less than 30 mg/dL. All subjects were recruited prospectively. Before the study onset, patients from groups A and C had not received any pharmacotherapy.
The exclusion criteria included type 1 or type 2 diabetes mellitus, prolactinoma, mixed pituitary tumors (secreting prolactin and other pituitary hormones), macroprolactinemia, any thyroid disorder, polycystic ovary syndrome, hypopituitarism, primary hypogonadism, myocardial infarction or stroke within 6 months preceding the study, symptomatic congestive heart failure, moderate or severe arterial hypertension (European Society of Cardiology/European Society of Hypertension grade 2 or 3), impaired renal or hepatic function, pregnancy or lactation, having received any treatment (with the exception of bromocriptine in group B), and poor patient compliance.
Study Design
Atorvastatin (40 mg) was administered once daily in the evening for 12 weeks, and no changes in dosage were allowed during this time. Moreover, throughout the study, all patients continued to comply with the lifestyle modifications (total fat intake <30% of total energy intake, saturated fat intake <7% of energy consumed, cholesterol intake <200 mg per day, an increase in fiber intake to 15 g per 1000 kcal, moderate to vigorous exercise for at least 30 minutes per day). The average dietary adherence was assessed once a month by the food frequency questionnaire and analysis of 3 days' eating diaries. The questionnaire evaluated how often in the past months the patient had consumed each of the 20 most commonly used meals of Polish cuisine. Food intake frequency was assessed in terms of the following 6 categories: everyday, 5-6 times per week, 3-4 times per week, 1-2 times per week, less than once per week, and never. Treatment compliance, investigated at each visit by tablet counts, was regarded as satisfactory if the number of tablets taken by a patient ranged from 90% to 110%.
Laboratory Assays
Venous blood samples were drawn from the antecubital vein between 8:00 and 9:00 AM, at least 12 hours after the last meal in the first and last days of the study, and were assessed in duplicate. Plasma levels of total cholesterol (high-density lipoprotein [HDL] cholesterol, LDL cholesterol, and triglycerides), glucose, uric acid, and creatinine were assayed by routine techniques using commercially available kits. Circulating levels of hormones (prolactin, thyrotropin, and insulin), high-sensitivity C-reactive protein (hsCRP), and homocysteine were assessed by means of a 2-site sandwich immunoassay using direct chemiluminometric technology (Advia Centaur XP Immunoassay System, Siemens Healthcare, Warsaw, Poland). Fibrinogen was measured by the Clauss technique in an automated BCS XP analyzer (Siemens Healthcare, Warsaw, Poland). The homeostatic model assessment 1 of insulin resistance (HOMA1-IR) was calculated as follows: fasting glucose (mg/dL) × fasting insulin (mIU/L)/405. The estimated glomerular filtration rate was calculated using the Modification Diet in Renal Disease Study equation (175 × serum creatinine −1.154 × age −0.203 × 0.742).
Statistical Analysis
To achieve approximately normal distributions, skewed variables were natural log-transformed. Mean absolute values in the study groups, as well as percentage changes from baseline after adjustment for baseline values (reflecting the strength of atorvastatin action) were compared using 1-way analysis of covariance followed by the post hoc Bonferroni test. The differences between the means of variables within the same treatment group were analyzed with Student paired t-test. For categorical variables, χ 2 test was used. Correlations were assessed using the Pearson correlation coefficient (r). Values of P < .05 were considered statistically significant. All statistical analyses were performed using the Statistica 12.0 PL software package (number: JPZP507D199115ARCN-E, StatSoft Polska, Kraków, Poland).
Results
Demographic data and baseline results are shown in Table 1 . At the beginning of the study, there was no difference between the treatment groups in terms of age, body mass index and plasma levels of glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and thyrotropin. Expectedly, prolactin levels were higher in group A than in groups B and C. Circulating levels of uric acid, hsCRP, homocysteine, and fibrinogen were higher in group A than in groups B and C. However, they did not differ between groups B and C. HOMA1-IR was not significantly higher in group A than in groups B (P = .062) and C (P = .083). In group B, bromocriptine was administered at the daily dose of 4.8 ± 1.3 mg for 25 ± 7 weeks (time range 12-56 weeks). No significant adverse effects were observed during the study, and all patients completed the study protocol.
Atorvastatin administered to all studied groups reduced plasma levels of total and LDL cholesterol but did not affect the body mass index, the estimated glomerular filtration rate, or the circulating levels of HDL cholesterol, triglycerides, glucose, prolactin, and thyrotropin (Table 2 ). In groups B and C, but not in group A, atorvastatin decreased circulating levels of 86 (15) 88 (18) 91 (22) HDL indicates high-density lipoproteins; HOMA1-IR, the homeostatic model assessment 1 of insulin resistance ratio; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoproteins. 1 Women with untreated hyperprolactinemia. 2 Bromocriptine-treated women with hyperprolactinemia. 3 Drug-naive women with prolactin levels within the reference range. 4 Patients may have had 1 or more symptoms or signs suggestive of elevated prolactin levels. 5 All patients from group B were treated with bromocriptine because of hyperprolactinemia. 6 The absence of patients with galactorrhea in group A probably results from the fact that the study included only subjects with mild or moderate hyperprolactinemia. a P < .05, b P < .001 vs group B; c P < .05, d P < .01, e P < .001 vs group C.
uric acid, hsCRP, homocysteine, and fibrinogen. In group A, but not in the remaining groups of patients, atorvastatin tended to increase HOMA1-IR (P = .067). The effect of atorvastatin on circulating levels of total cholesterol, LDL cholesterol, uric acid, hsCRP, homocysteine, and fibrinogen was stronger in groups B and C than in group A. On the last day of the study, there were differences between group A and groups B and C in total cholesterol, LDL cholesterol, prolactin, HOMA1-IR, uric acid, hsCRP, homocysteine, and fibrinogen (Table 2) . In all study groups, circulating levels of uric acid, hsCRP, homocysteine, and fibrinogen correlated with plasma levels of total cholesterol (r values between 0. (15) 88 (18) 91 (22) At the end of the study 90 (16) 91 (14) 87 (16) HDL indicates high-density lipoproteins; HOMA1-IR, the homeostatic model assessment 1 of insulin resistance ratio; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoproteins. 1 Women with untreated hyperprolactinemia. 2 Bromocriptine-treated women with hyperprolactinemia. 3 Drug-naive women with prolactin levels within the reference range. a P < .05, b P < .01, c P < .001 vs group B; d P < .05, e P < .01, f P < .001 vs group C; g P < .05, h P < .01, i P < .001 vs baseline value; j P < .05, k P < .001 statistically different vs the effect of atorvastatin in group A. levels of thyrotropin (r = 0.26, P < .05), uric acid (r = 0.28, P < .05), hsCRP (r = 0.42, P < .001), homocysteine (r = 0.32, P < .05), and fibrinogen (r = 0.35, P < .01); (2) baseline levels of prolactin and HOMA1-IR (r = 0.38, P < .001); and (3) baseline levels of uric acid, hsCRP, homocysteine, fibrinogen, and HOMA1-IR (r values between 0.29 [P < .05] and 0.39 [P < .001]). In this group of patients there were correlations between atorvastatininduced changes in HOMA1-IR and baseline prolactin levels (r = 0.31, P < .05). The reduction in uric acid, hsCRP, homocysteine, and fibrinogen was unrelated to the degree of lipid profile improvement.
Discussion
Dopamine agonist therapy is recommended to lower prolactin levels, decrease tumor size, and restore gonadal function for symptomatic patients with prolactin-secreting pituitary microadenomas or macroadenomas. 22 Because of severe hyperprolactinemia, such patients usually develop numerous symptoms and/or signs of prolactin excess. Therefore, for ethical reasons, we excluded patients with pituitary adenomas and markedly elevated prolactin levels. Unlike subjects with prolactinoma, no treatment is necessary in asymptomatic patients with nontumoral hyperprolactinemia. 22 In turn, current guidelines recommend neither for nor against the obligatory use of dopamine agonists in oligosymptomatic patients with mild or moderate nontumoral hyperprolactinemia for participants in our study. Arguments against the use of dopamine agonists are their adverse effects and the probably benign nature of mild to moderate nontumoral hyperprolactinemia. In a long-term prospective study of oligosymptomatic women with elevated prolactin levels who were not treated and who underwent yearly clinical, hormonal, and radiographic evaluation for an average of 5.2 years, 30% of all patients reported improvement in clinical symptoms. 23 Moreover, in 34 of 41 patients followed for up to 11 years, serum prolactin levels remained the same, decreased, or returned to normal. 24 The results of both studies suggest that most patients with mild or moderate hyperprolactinemia are unlikely to have progression of their disease.
The results of our study show that untreated mild to moderate nontumoral hyperprolactinemia is accompanied by elevated levels of extralipid cardiometabolic risk factors. Because even small differences in levels of uric acid, hsCRP, homocysteine, and fibrinogen are associated with various risks of cardiometabolic complications, chronically elevated prolactin levels may predispose to the development and progression of atherosclerotic disorders and diabetes mellitus. [25] [26] [27] [28] Although lipid levels slightly correlated with plasma levels of extralipid markers assessed in our study, differences in baseline concentrations of uric acid, hsCRP, homocysteine, and fibrinogen do not seem to result from dyslipidemia because all groups of patients were characterized by similar levels of plasma lipids. Interestingly, previously we found that both bromocriptine and cabergoline reduced circulating levels of cardiovascular risk factors, but the effect of cabergoline, which is a more potent prolactin-lowering agent than bromocriptine, was stronger. 29 These findings and the results of our current study may suggest that oligosymptomatic or asymptomatic women with hyperprolactinemia should be treated with dopamine agonists to reduce cardiometabolic risk. From a cardiometabolic point of view, dopaminergic agents are better drugs than those used by some symptomatic women with hyperprolactinemia oral contraceptive pills, which were found to increase circulating levels of cardiometabolic risk factors. 30 As the results of the present study suggest, normalization of prolactin decreases plasma levels of uric acid, hsCRP, homocysteine, and fibrinogen to the level observed in women with prolactin levels within the reference range. This means that cardiovascular risk of effectively treated hyperprolactinemic women is similar to that observed in drug-naive women without hyperprolactinemia.
However, the most important finding of our study is that elevated prolactin levels ameliorated the lipidlowering effects of atorvastatin and completely abolished its pleiotropic effects. Moreover, in women with hyperprolactinemia, lipid-lowering and extralipid effects of atorvastatin negatively correlated with baseline levels of this hormone. In opposition to hyperprolactinemic women, atorvastatin action was undisturbed in women in whom bromocriptine had normalized elevated prolactin levels. All these findings taken together may indicate that even mildly or moderately increased prolactin levels significantly reduce the clinical effectiveness of statin therapy. If this conclusion is correct, at least 2 groups of patients should be considered as candidates for measuring prolactin levels. The first group includes hypercholesterolemic individuals with signs/symptoms suggestive of hyperprolactinemia, such as oligomenorrhea, infertility, galactorrhea, loss of libido, and sexual dysfunction. 31 The second group are patients in whom HMG-CoA reductase inhibitors reduce total and LDL cholesterol but this effect is weaker than anticipated. In the light of our research, patients with concomitantly elevated prolactin and LDL cholesterol levels are candidates for combined statin/dopamine agonist therapy. In line with this explanation, atorvastatin produced a similar effect on plasma lipids and other cardiometabolic risk factors in patients treated with bromocriptine and metformin. 32 Because in our study atorvastatin did not affect prolactin levels, this hormone may be measured only once, preferably at the beginning of statin therapy.
Statins increase the risk of developing type 2 diabetes mellitus, and this risk is more pronounced in patients receiving intensive-dose statin than in subjects receiving moderate-dose statin therapy. 33 In our study no changes in plasma glucose were observed in any treatment groups, which may be a consequence of a short treatment period, moderate statin dose, and/or relatively low values of HOMA1-IR in groups B and C. However, in group A, atorvastatin impaired insulin sensitivity, and this negative effect on HOMA1-IR may be explained by its potentiating atorvastatin action by the unfavorable impact of prolactin excess on insulin resistance. 34 In line with this view, baseline HOMA1-IR was slightly higher in women with untreated hyperprolactinemia than in women with prolactin levels within the reference range. In the case of women from group B, a neutral effect of atorvastatin may be also attributed to bromocriptine treatment, which is known to improve glucose homeostasis (a quick-release form of bromocriptine is approved for use in type 2 diabetes mellitus). 35 We can only speculate about molecular mechanisms responsible for the obtained results. The absence of correlations between the effect of atorvastatin on plasma lipids and its effects on other cardiometabolic risk factors is an argument against the view that different effects on uric acid, hsCRP, homocysteine, and fibrinogen are secondary to various hypolipidemic effects of atorvastatin in patients with and without hyperprolactinemia. More convincing is its association with pleiotropic effects of atorvastatin, particularly with its impact on the synthesis of nonsterol isoprenoids derived from the mevalonate pathway (especially farnesyl and geranylgeranyl pyrophosphates), which are involved in the regulation of many cellular processes. 36 In line with this hypothesis, prolactin was found to stimulate G proteins in the target tissues. 37 Moreover, HMG-CoA reductase inhibitors affect several important downstream transcription factors, including an inhibitory effect on nuclear factor-κB, a stimulatory effect on the expression and activity of peroxisome proliferator-activated receptors-α, as well as an inhibitory effect on the leukocyte function-associated antigen-1 intercellular adhesion molecule-1 interaction. 38, 39 These statin pathways may be disturbed by high prolactin levels. This explanation seems to be supported by the finding that prolactin induced nuclear factor-κB 40 and stimulated adhesion of circulating mononuclear cells to endothelial cells via affecting leukocyte function-associated antigen-1. 41 Finally, the obtained results may be explained by an impact on peroxisome proliferator-activated receptors-α. In line with this explanation, the expression of peroxisome proliferator-activated receptors-α is enhanced by statins, 7 whereas prolactin-lowering agents reduced circulating levels of free fatty acids, which are endogenous ligands for these receptors. 42 Our study has several limitations that must be taken into consideration. The major limitation is the small sample size and short treatment duration. Moreover, the study did not investigate clinical outcomes, including morbidity or mortality. Because the study population consisted of only women, it is not certain whether the impact of atorvastatin is similar in men with elevated and normal prolactin levels. Furthermore, the study protocol does not make it possible to conclude whether the obtained results represent a class effect or are related to unique properties of this drug.
Conclusion
Our study is the first to show that elevated prolactin levels disturb statin action on plasma lipids, uric acid, hsCRP, homocysteine, and fibrinogen. This unfavorable impact, not observed in bromocriptinetreated women, is inversely correlated with the baseline prolactin levels. The obtained results suggest that the cardiometabolic effects of HMG-CoA reductase inhibitors may be partially determined by the prolactin status of a patient. Further research, however, is required to support our findings.
